References
- Advisory Committee for Pharmaceutical Science. Clinical Pharmacology Section meeting transcripts. 3 November 2004, 2004, (available at: http://www.fda.gov/ohrms/dockets/ac/04/transcripts/2004-4079T1.htm)
- Advisory Committee for Pharmaceutical Science. Clinical Pharmacology Subcommittee meeting slides. 18–19 October 2006, 2006, (available at: http://www.fda.gov/ohrms/dockets/ac/06/slides/2006-4248s1-index.htm)
- ALLEGRA. (Fexofenadine) labeling. 2005, (available at: http://www.fda.gov/cder/foi/label/2005/020872s015lbl.pdf)
- Ambudkar SV, Kimchi-Sarfaty C, Sauna ZE, Gottesman MM. P-glycoprotein: From genomics to mechanism. Oncogene 2003; 22(47)7468–7485
- Antiviral Drugs Advisory Committee Meeting. FDA presentations, drug interactions. 19 May 2005, 2005, (available at: http://www.fda.gov/ohrms/dockets/ac/05/slides/2005-4139S1_10_FDA-Zhang.ppt)
- APTIVUS. Clinical Pharmacology Biopharmaceutics Review. 2005, (available at: http://www.fda.gov/cder/foi/nda/2005/21814_000_AptivusTOC.htm)
- APTIVUS. (Tipranavir) labeling. 2007, (available at: http://www.fda.gov/cder/foi/label/2007/021814s003lbl.pdf)
- BIAXIN. (Clarithromycin) labeling. 2007, (available at: http://www.fda.gov/cder/foi/label/2007/050662s040,050698s022,050775s011lbl.pdf)
- Boyd RA, Stern RH, Stewart BH, Wu X, Reyner EL, Zegarac EA, Randinitis EJ, Whitfield L. Atorvastatin coadministration may increase digoxin concentrations by inhibition of intestinal P-glycoprotein-mediated secretion. Journal of Clinical Pharmacology 2000; 40(1)91–98
- Brown GR. Cephalosporin-probenecid drug interactions. Clinical Pharmacokinetics 1993; 24(4)289–300
- CDER Drug Developement and Drug Interactions. Drug development and drug interactions. 2007, (available at: http://www.fda.gov/cder/drug/drugInteractions/default.htm)
- CHANTIX. (Varenicline) labeling. 2007, (available at: http://www.fda.gov/cder/foi/label/2007/021928s003lbl.pdf)
- CRESTOR. (Rosuvastatin) labeling. 2005, (available at: http://www.fda.gov/cder/foi/label/2005/21366slr005lbl.pdf)
- Cvetkovic M, Leake B, Fromm MF, Wilkinson GR, Kim RB. OATP and P-glycoprotein transporters mediate the cellular uptake and excretion of fexofenadine. Drug Metabolism and Disposition 1999; 27(8)866–871
- Cvetkovic RS, Goa KL. Lopinavir/ritonavir: A review of its use in the management of HIV infection. Drugs 2003; 63(8)769–802
- De SM, Schoors DF, De MG, Verbesselt R, Goldberg MR, Fitzpatrick V, Somers G. Effect of multiple doses of losartan on the pharmacokinetics of single doses of digoxin in healthy volunteers. British. Journal of Clinical Pharmacology 1995; 40(6)571–575
- Digoxin Labeling. Digoxin labeling. 2004, (available at: http://www.fda.gov/cder/foi/label/2004/21648lbl.pdf)
- Dorian P, Strauss M, Cardella C, David T, East S, Ogilvie R. Digoxin-cyclosporine interaction: Severe digitalis toxicity after cyclosporine treatment. Clinical Investigation in Medicine 1988; 11(2)108–112
- Draft Guidance for Industry. Drug interaction studies — study design, data analysis, and implications for dosing and labeling. 2006, (available at: http://www.fda.gov/cder/guidance/6695dft.pdf)
- Eberl S, Renner B, Neubert A, Reisig M, Bachmakov I, Konig J, Dorje F, Murdter TE, Ackermann A, Dormann H, Gassmann KG, Hahn EG, Zierhut S, Brune K, Fromm MF. Role of p-glycoprotein inhibition for drug interactions: Evidence from in vitro and pharmacoepidemiological studies. Clinical Pharmacokinetics 2007; 46(12)1039–1049
- Fei YJ, Ganapathy V, Leibach FH. Molecular and structural features of the proton-coupled oligopeptide transporter superfamily. Progress in Nucleic Acid Research Molecular Biology 1998; 58: 239–261
- Feng B, Obach RS, Burstein AH, Clark DJ, De Morais SM, Faessel HM. Effect of human renal cationic transporter inhibition on the pharmacokinetics of varenicline, a new therapy for smoking cessation: An in vitro–in vivo study. Clinical Pharmacology and Therapeutics 2008; 83(4)567–576
- Fromm MF, Kim RB, Stein CM, Wilkinson GR, Roden DM. Inhibition of P-glycoprotein-mediated drug transport: A unifying mechanism to explain the interaction between digoxin and quinidine. Circulation 1999; 99(4)552–557
- Geick A, Eichelbaum M, Burk O. Nuclear receptor response elements mediate induction of intestinal MDR1 by rifampin. Journal of Biological Chemistry 2001; 276(18)14581–14587
- Guidance for Industry. Guidance for industry: Waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. 2000, (available at: http://www.fda.gov/cder/guidance)
- Hager WD, Fenster P, Mayersohn M, Perrier D, Graves P, Marcus FI, Goldman S. Digoxin–quinidine interaction. Pharmacokinetic evaluation. New England Journal of Medicine 1979; 300(22)1238–1241
- Hager WD, Mayersohn M, Graves PE. Digoxin bioavailability during quinidine administration. Clinical Pharmacology and Therapeutics 1981; 30(5)594–599
- Huang S-M, Strong JM, Zhang L, Reynolds SK, Nallani S, Temple R, Abraham S, Al, Habet S, Baweja RK, Burckart GJ. New era in drug interactions evaluation: FDA update on CYP enzymes, transporters and the guidance process. Journal of Clinical Pharmacology 2008, doi:10.1177/0091270007312153
- Huang SM, Temple R, Throckmorton DC, Lesko LJ. Drug interaction studies: Study design, data analysis, and implications for dosing and labeling. Clinical Pharmacology and Therapeutics 2007; 81(2)298–304
- Jalava KM, Partanen J, Neuvonen PJ. Itraconazole decreases renal clearance of digoxin. Therapy and Drug Monitoring 1997; 19(6)609–613
- JANUVIA. (Sitagliptin). 2007, (available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm)
- Keogh JP, Kunta JR. Development, validation and utility of an in vitro technique for assessment of potential clinical drug–drug interactions involving P-glycoprotein. European Journal of Pharmacology Science 2006; 27(5)543–554
- Kim RB. Organic anion-transporting polypeptide (OATP) transporter family and drug disposition. European Journal of Clinical Investigation 2003; 33(Suppl. 2)1–5
- Kirimli O, Kalkan S, Guneri S, Tuncok Y, Akdeniz B, Ozdamar M, Guven H. The effects of captopril on serum digoxin levels in patients with severe congestive heart failure. International Journal of Clinical Pharmacology and Therapeutics 2001; 39(7)311–314
- Koepsell H, Schmitt BM, Gorboulev V. Organic cation transporters. Reviews in Physiology, Biochemistry and Pharmacology 2003; 150: 36–90
- Lehmann JM, McKee DD, Watson MA, Willson TM, Moore JT, Kliewer SA. The human orphan nuclear receptor PXR is activated by compounds that regulate CYP3A4 gene expression and cause drug interactions. Journal of Clinical Investigation 1998; 102(5)1016–1023
- Lin JH. Drug–drug interaction mediated by inhibition and induction of P-glycoprotein. Advances in Drug Delivery Reviews 2003; 55(1)53–81
- Mahgoub AA, El-Medany AH, Abdulatif AS. A comparison between the effects of diltiazem and isosorbide dinitrate on digoxin pharmacodynamics and kinetics in the treatment of patients with chronic ischemic heart failure. Saudi Medical Journal 2002; 23(6)725–731
- Martin PD, Kemp J, Dane AL, Warwick MJ, Schneck DW. No effect of rosuvastatin on the pharmacokinetics of digoxin in healthy volunteers. Journal of Clinical Pharmacology 2002; 42(12)1352–1357
- Meier PJ, Stieger B. Bile salt transporters. Annual Reviews in Physiology 2002; 64: 635–661
- Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T. The organic anion transporter (OATP) family. Drug Metabolism and Pharmacokinetics 2004; 19(3)171–179
- Mizuno N, Niwa T, Yotsumoto Y, Sugiyama Y. Impact of drug transporter studies on drug discovery and development. Pharmacology Reviews 2003; 55(3)425–461
- Oosterhuis B, Jonkman JH, Andersson T, Zuiderwijk PB, Jedema JN. Minor effect of multiple dose omeprazole on the pharmacokinetics of digoxin after a single oral dose. British Journal of Clinical Pharmacology 1991; 32(5)569–572
- Physicians’ Desk. Labeling information. 2005, (available at: http://www.fda.gov/cder/approval/index.htm and http://pdrel.thomsonhc.com/pdrel/librarian)
- RANEXA. (Ranolazine). 2007, (available at: http://www.accessdata.fda.gov/scripts/cder/drugsatfda/index.cfm)
- Rengelshausen J, Goggelmann C, Burhenne J, Riedel KD, Ludwig J, Weiss J, Mikus G, Walter-Sack I, Haefeli WE. Contribution of increased oral bioavailability and reduced nonglomerular renal clearance of digoxin to the digoxin–clarithromycin interaction. British Journal of Clinical Pharmacology 2003; 56(1)32–38
- Rodin SM, Johnson BF, Wilson J, Ritchie P, Johnson J. Comparative effects of verapamil and isradipine on steady-state digoxin kinetics. Clinical Pharmacology and Therapeutics 1988; 43(6)668–672
- Sadeque AJ, Wandel C, He H, Shah S, Wood AJ. Increased drug delivery to the brain by P-glycoprotein inhibition. Clinical Pharmacology and Therapeutics 2000; 68(3)231–237
- Sakaeda T, Fujino H, Komoto C, Kakumoto M, Jin JS, Iwaki K, Nishiguchi K, Nakamura T, Okamura N, Okumura K. Effects of acid and lactone forms of eight HMG-CoA reductase inhibitors on CYP-mediated metabolism and MDR1-mediated transport. Pharmaceutical Research 2006; 23(3)506–512
- Schinkel AH, Wagenaar E, Mol CA, Van DL. P-glycoprotein in the blood–brain barrier of mice influences the brain penetration and pharmacological activity of many drugs. Journal of Clinical Investigation 1996; 97(11)2517–2524
- Shitara Y, Sato H, Sugiyama Y. Evaluation of drug–drug interaction in the hepatobiliary and renal transport of drugs. Annual Reviews in Pharmacology and Toxicology 2005; 45: 689–723
- Simonson SG, Raza A, Martin PD, Mitchell PD, Jarcho JA, Brown CD, Windass AS, Schneck DW. Rosuvastatin pharmacokinetics in heart transplant recipients administered an antirejection regimen including cyclosporine. Clinical Pharmacology and Therapeutics 2004; 76(2)167–177
- Sun H, Dai H, Shaik N, Elmquist WF. Drug efflux transporters in the CNS. Advances in Drug Delivery Reviews 2003; 55(1)83–105
- Sweet DH, Bush KT, Nigam SK. The organic anion transporter family: From physiology to ontogeny and the clinic. American Journal of Physiology and Renal Physiology 2001; 281(2)F197–F205
- Tsuji A. Transporter-mediated drug interactions. Drug Metabolism and Pharmacokinetics 2002; 17(4)253–274
- Westphal K, Weinbrenner A, Giessmann T, Stuhr M, Franke G, Zschiesche M, Oertel R, Terhaag B, Kroemer HK, Siegmund W. Oral bioavailability of digoxin is enhanced by talinolol: Evidence for involvement of intestinal P-glycoprotein. Clinical Pharmacology and Therapeutics 2000; 68(1)6–12
- Williams GC, Sinko PJ. Oral absorption of the HIV protease inhibitors: A current update. Advances in Drug Delivery Reviews 1999; 39(1–3)211–238
- Wright SH. Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicology and Applied Pharmacology 2005; 204(3)309–319
- Wu CY, Benet LZ. Predicting drug disposition via application of BCS: Transport/absorption/elimination interplay and development of a biopharmaceutics drug disposition classification system. Pharmaceutical Research 2005; 22(1)11–23
- Zhang L, Strong JM, Qiu W, Lesko LJ, Huang SM. Scientific perspectives on drug transporters and their role in drug interactionst. Molecular Pharmaceutics 2006; 3(1)62–69
- Zhang Y, Mireles R, Xu J, Mills J, De Morais S, Menard C., Polzer R, Janiszewski J. In vitro evaluation of relative inhibitory potency and substrate affinity of three macrolides to P-glycoprotein for predicting drug–drug interactions. Abstract for the 16th American Association of Pharmaceutical Scientists Annual Meeting Toronto, Ont. Canada 29 October–2 November 2002, 2002